SAN DIEGO — News of the Food and Drug Administration’s historic approval of the first gene therapies for sickle cell disease sparked discussion, debate, and,
SAN DIEGO — When the first lupus patient received CAR-T therapy, researchers watched in amazement as her autoimmune disease rapidly went into remission. Then, they monitored
SAN DIEGO — Researchers on Saturday presented an unusual case of a T cell lymphoma marked with a CAR, the key synthetic protein in CAR-T
STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a
Welcome to TDR’s review of the Top 5 Psychedelic Developments for the week of December 4. Aside from presenting a synopsis of events, we provide
SLE is a heterogeneous disease, which can cause many different manifestations and symptoms, and traditionally did not have many treatment options.
Women 50 or older who de-escalated to less-frequent mammography three years after curative surgery for early-stage breast cancer had similar outcomes to women who received
Patients with low-risk ductal carcinoma in situ (DCIS) who skipped adjuvant radiotherapy after breast-conserving surgery had comparable five-year outcomes to those with high-risk DCIS who
The University of Texas MD Anderson Cancer Center and Rigel Pharmaceuticals, Inc. today announced a multi-year strategic development collaboration to expand the evaluation of olutasidenib
Data from Australian researchers could partly explain why a trial of a new drug for diabetes, was recently halted because it was found to be